MAPK3 and melanoma: BRAFi + MEKi is now the standard for consistency care for melanoma with BRAFV600E/K 6,7; however, acquired resistance still emerges, typically through reactivation of ERK1/2, and this is fuelling the development of ERK1/2 inhibitors46.